Auto Draft

AbbVie Inc. (NYSE:ABBV) ranks among the 14 safe stocks to buy now for a starter stock portfolio.

RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages

On February 24, RBC Capital began coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a price target of $260. While mainstream opinion appears to be catching up on the company’s Skyrizi and Rinvoq sales, the firm states that AbbVie Inc. (NYSE:ABBV) still remains in the early stages of expansion and will continue to exceed.

RBC Capital warned that investors are overlooking long-term growth, noting that this decade has no substantial loss-of-exclusivity scenarios that do not rely on mergers and acquisitions.

The company claims that AbbVie Inc. (NYSE:ABBV) is trading at under 16x earnings, which puts it closer to pharma firms that are experiencing a significant loss of exclusivity incidents compared to high-growth companies. At the same time, AbbVie Inc. (NYSE:ABBV) is producing impressive earnings-per-share growth of about 17%, compared to competitors’ 6%.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches & develops, manufactures, commercializes, and sells medicines and therapies worldwide.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.